

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>New Leaf Biopharma Opportunities II, L.P.</u>			2. Issuer Name and Ticker or Trading Symbol <u>Harpoon Therapeutics, Inc. [HARP]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/25/2023			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 820			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	NEW YORK NY 10010		Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/25/2023		P		1,372,000 ⁽¹⁾	A	(1)	1,463,386 ⁽²⁾	D ⁽³⁾⁽⁴⁾	
Common Stock	10/25/2023		P		171,500 ⁽¹⁾	A	(1)	395,783 ⁽²⁾	I	See Footnote ⁽⁵⁾⁽⁶⁾
8.000% Series A Redeemable Preferred Stock								10,000 ⁽⁷⁾	D ⁽³⁾⁽⁴⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Common Stock Warrant (Right to Buy)	\$5.8345 ⁽⁸⁾	10/25/2023		P		686,000		10/25/2023	10/25/2026	Common Stock 686,000	(1)	686,000	D ⁽³⁾⁽⁴⁾	
Common Stock Warrant (Right to Buy)	\$5.8345 ⁽⁸⁾	10/25/2023		P		85,750		10/25/2023	10/25/2026	Common Stock 85,750	(1)	85,750	I	See Footnote ⁽⁵⁾⁽⁶⁾

1. Name and Address of Reporting Person*
New Leaf Biopharma Opportunities II, L.P.

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 820

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

1. Name and Address of Reporting Person*
New Leaf Ventures III, L.P.

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 830

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[New Leaf Venture Associates III, L.P.](#)

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 830

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[New Leaf Venture Management III, L.L.C.](#)

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 830

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[New Leaf BPO Associates II, L.P.](#)

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 830

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[New Leaf BPO Management II, L.L.C.](#)

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 830

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Lathi Vijay K](#)

(Last) (First) (Middle)
C/O NEW LEAF VENTURES
156 FIFTH AVENUE, SUITE 830

(Street)
NEW YORK NY 10010

(City) (State) (Zip)

Explanation of Responses:

- Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of \$5.8345 per share of Common Stock and accompanying warrant.
- Shares reflect a 1:10 reverse stock split of the Issuer's Common Stock effective September 1, 2023.
- These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("BPO-II"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. ("NLBA-II"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. ("BPO Management-II"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the "BPO-II Managing Directors") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The sole general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- Ronald Hunt, a board member of the Issuer, and Vijay K. Lathi (collectively, the "NLV-III Managers") are managing directors of Management-III and may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- The terms of the Series A Preferred Stock are set forth in the Certificate of Designation filed as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 27, 2023.
- The exercise price is also subject to adjustment pursuant to the Common Stock Warrant issued on October 25, 2023.

Remarks:

[New Leaf Ventures III, L.P., By: New Leaf Venture Associates III, L.P., its general partner, By: New Leaf Venture Management III, L.L.C., its general partner, By: /s/ Craig Slutzkin, Chief Financial Officer](#) [10/27/2023](#)
[New Leaf Venture Associates III, L.P., By: New Leaf Venture Management III, L.L.C., its general partner, by /s/ Craig Slutzkin, Chief Financial Officer](#) [10/27/2023](#)
[New Leaf Venture Management III, L.L.C., By: /s/ Craig Slutzkin, Chief Financial Officer](#) [10/27/2023](#)
[New Leaf Biopharma Opportunities II, L.P., By: New Leaf BPO Associates II, L.P., its general partner, By: New Leaf BPO Management II, L.L.C., its general partner, By: /s/ Craig Slutzkin, Chief Financial Officer](#) [10/27/2023](#)
[New Leaf BPO Associates II, L.P., By: New Leaf BPO Management II, L.L.C., its general partner, By: /s/ Craig Slutzkin, Chief Financial Officer](#) [10/27/2023](#)
[New Leaf BPO Management II, L.L.C., By: /s/ Craig Slutzkin, Chief Financial Officer](#) [10/27/2023](#)
[/s/ Vijay K. Lathi, Vijay K. Lathi](#) [10/27/2023](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.